Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.
Ibiayi Dagogo-JackMarguerite RooneyJessica J LinRebecca J NagyBeow Y YeapHarper G HubbelingEmily ChinJennifer AckilAnna F FaragoAaron N HataJochen K LennerzJustin F GainorRichard B LanmanAlice T ShawPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
ALK resistance mutations increase with each successive generation of ALK TKI and may be underestimated by tumor genotyping. Sequential treatment with increasingly potent ALK TKIs may promote acquisition of ALK resistance mutations leading to treatment-refractory compound ALK mutations.